



Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Mitchele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowit Peter A. Jackman
Brian J. Del Buono
Mark fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Theodore A. Wood
Edward W. Yee
Grant E. Reed
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LUAnne M. DeSantis
Helene C. Carlson
Cynthia M. Bouchez
Jimothy A. Doyle
Gaby L. Longsworth

July 15, 2008

Lori A. Gordon Laura A. Vogel Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou W. Blake Coblentz James J. Pohl John T. Haran Mark W. Rygiel Michael R. Malek* Carla Ji-Eun Kim Doyle A. Siever* Ulrike Winkler Jenks Paul A. Cabvo C. Matthew Rozier* Randall K. Baldwin Daniel J. Nevrivy
Lori M. Brandes
Jeffrey K. Mills*
Mita Mukherjee*
Scott M. Woodhouse*
Christian A. Camarce*
Richard D. Coller Ill*
Keisha Hytton-Rodic
Bonnie Nannenga-Combs
Alyssa K. Sandrowitz
Jonathan M. Strang*
Ishan P. Weerakoon*

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Peter A. Socarras Danielle L. Letting Steven C. Oppenheimer

Mail Stop: Amendment

Aaron S. Lukas Gaurav Asthana Stephanie L. Elmer Robert E. Bakin Salvador M. Bezos Yasser Mourtada

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie Christopher P. Wrist David C. Isaacson

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8610 INTERNET ADDRESS: SELMER@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Appl. No. 10/593,627; § 371 Filing Date: September 21, 2006

For: **Fo** Inventor:

Formulations of Ramipril or: Reynir EYJOLFSSON

Our Ref:

2476.0090000/RWE/SLE

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 2. One (1) page of Form PTO/SB/08A citing twenty-six (26) documents;
- 3. A copy of nine (9) of the cited documents FP1-FP9;
- 4. One (1) page of Form PTO/SB/08B citing twelve (12) documents;
- 5. A copy of the twelve (12) cited documents NPL1-NPL12; and
- 6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of the documents and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents July 15, 2008 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Stephante L. Elmer Agent for Applicants Registration No. 59,244

RWE/SLE:las Enclosures

845548_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

EYJOLFSSON, Reynir

Appl. No.: 10/593,627

§ 371 Filing Date: September 21, 2006

Formulations of Ramipril For:

Confirmation No.: 1689

Art Unit:

1614

Examiner:

To Be Assigned

Atty. Docket: 2476.0090000/RWE/SLE

Information Disclosure Statement under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents FP1 to FP9 and NPL1 to NPL12 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, US1 to US17, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

Document FP1 was cited in a search report by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report that indicates the degree of relevance found by the foreign office is provided as document NPL12 in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38. Also, an English language translation is provided as document NPL1.

The Examiner's attention is directed to the following U.S. Patent Applications, which are directed to related technical subject matter:

- U.S. Patent Application No. 11/509,032, inventors Harrison, P., et al., filed August 24, 2006; published on March 8, 2007 as US 2007/00053975, cited herein as document US12;
- U.S. Patent Application No. 11/508,916, inventors Harrison, P., et al., filed August 24, 2006; published on May 3, 2007, as US 2007/0098782, cited herein as document US13;
- U.S. Patent Application No. 11/777,849, inventor Eyjolfsson, R., filed July 13, 2007; published on November 1, 2007, as US 2007/0254030, cited herein as document US14;
- U.S. Patent Application No. 11/273,575, inventors Harrison, P., et al., filed November 15, 2005; published on November 8, 2007 as US 2007/0259941, cited herein as document **US15**;
- U.S. Patent Application No. 11/976,859, inventors Harrison, P., et al., filed October 29, 2007; published on May 8, 2008, as US 2008/0108687, cited herein as document **US16**; and
- U.S. Patent Application No. 11/976,865, inventors Harrison, P., et al., filed October 29, 2007; published on May 8, 2008, as US 2008/0108688, cited herein as document US17.

In accordance with the Federal Circuit decision in *Dayco Prods., Inc. v. Total Containment, Inc.* 329 F.3d 1358 (Fed. Cir. 2003), Applicants submit herewith the following Office Actions and Amendment and Replies to Office Actions under 37 C.F.R. § 1.111 and 37 C.F.R. § 1.116 from:

the related co-pending U.S. Patent Application No. 11/509,032, as documents NPL2 and NPL3;

the related co-pending U.S. Patent Application No. 11/508,916, as documents NPL4 to NPL8;

the related co-pending U.S. Patent Application No. 11/976,865, as document NPL9; and

the related co-pending U.S. Patent Application No. 11/777,849 as documents NPL10 and NPL11.

The identification of the above-mentioned U.S. Patent Applications and Office Actions is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

8TERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Agent for Applicant Registration No. 59,244

Date: ___ July 15, 2008

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 825615v1